Phio Pharmaceuticals announced it will present results from its completed Phase 1b clinical trial of PH-762, a potential non-surgical treatment for skin cancers, at the Life Sciences Future 2026 Conference. CEO Robert Bitterman will discuss the favorable safety profile of PH-762 and outline next steps to advance clinical development. The presentation aims to attract investors and strategic partners by highlighting the promise of Phio's INTASYL siRNA gene silencing technology in cancer treatment. Management will also hold one-on-one meetings during the event to further engage stakeholders.
Phio Pharmaceuticals clinical update is the subject, with this snapshot from Pluang's Health sector as of Sep 23, 2026 18:02 WIB: Out of 100 priced US Health stocks, 55 rose and 37 fell. Notable movers include CRON at USD 3.48 with a 1.46% gain and 100% sell order activity, DVA at USD 186.36 with a 1.44% gain and 80% sell order activity, and SNY at USD 41.90 with a 1.43% loss and 100% buy order activity.
MyRecipes, a brand under People Inc., has launched a new app offering over 100,000 tested recipes from popular food brands like Allrecipes and Food & Wine. The app allows users to save recipes from Instagram, TikTok, and other sites, making it a uniq...
Quantum eMotion Corp.'s subsidiary SKV Technology has received a Notice of Allowance from the USPTO for its SecureKey™ cryptographic technology patent, marking a key step toward patent issuance. SecureKey™ protects cryptographic keys during operation...
BacTech Environmental Corporation, a leader in bioleaching technology for metal recovery, will attend the Centurion One Capital 4th Annual Bahamas Summit from October 19-21, 2026. The event features presentations, panel discussions, and investor meet...
A Snap insider has sold 20,000 shares as the company's stock has declined by 27% over the last year. This insider sale may signal concerns about the stock's near-term prospects or a personal decision to liquidate holdings. Investors should watch for ...
Manpower has been recognized as a Star Performer and Leader in three Everest Group U.S. Contingent Talent and Strategic Solutions PEAK Matrix® assessments for 2026. This distinction highlights Manpower's significant year-over-year improvements in mar...
